# Clinical Trials Data BRAF - Document 41

# The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01688232

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Adult patient with newly diagnosed colorectal cancer.\n\* Patient with signed informed consent.\n\* Follow up made by the clinical center for inclusion or by a medical team in relation with the center.\n\nExclusion Criteria:",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Adult patient with newly diagnosed colorectal cancer.",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not specify\*\* whether a BRAF mutation is an inclusion or exclusion criteria. Therefore, we cannot determine from the provided information if a patient with a BRAF mutation would be eligible. More information about the trial's exclusion criteria is needed. The presence of a BRAF mutation could either be irrelevant to eligibility or a specific exclusion criterion, depending on the trial's design.